Premium
Progressive anemia following combination therapy with interferon‐α and interleukin‐2 in a patient with metastatic renal cell carcinoma
Author(s) -
HOSOKAWA YUKINARI,
KISHINO TATSUKI,
ONO TAKAMASA,
OYAMA NOBUO,
HAYASHI KUNIO,
MOMOSE HITOSHI
Publication year - 2004
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2004.00914.x
Subject(s) - medicine , renal cell carcinoma , alpha interferon , anemia , interferon alfa , interferon , carcinoma , interleukin 2 , oncology , gastroenterology , cytokine , immunology
Various toxicities have been observed during the treatment of advanced renal cell carcinoma with interferon‐α (IFN‐α) and/or interleukin‐2 (IL‐2). We report a case of severe anemia, which responded well to steroid therapy, in a patient receiving IL‐2 plus IFN‐α for metastatic renal cell carcinoma.